SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Thorstenson Sten)
 

Sökning: WFRF:(Thorstenson Sten) > Molecular subtyping...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005138naa a2200493 4500
001oai:DiVA.org:liu-88364
003SwePub
008130204s2013 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-172675
009oai:lup.lub.lu.se:d8f9d7ee-d6e1-43d6-8a98-041fdf2802d3
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-883642 URI
0247 a https://doi.org/10.3109/0284186X.2012.7119522 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1726752 URI
0247 a https://lup.lub.lu.se/record/34809712 URI
040 a (SwePub)liud (SwePub)uud (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Nilsson, Ceciliau Uppsala universitet,Centrum för klinisk forskning, Västerås,Enheten för onkologi,Vastmanland County Hospital, Sweden4 aut0 (Swepub:uu)cecni926
2451 0a Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact
264 1b Informa Healthcare,c 2013
338 a print2 rdacarrier
500 a Funding Agencies|Regional Research Foundation in Uppsala-Orebro||Lions Cancer Foundation||University Hospital, Uppsala||Vastmanlands Research Foundation||
520 a Background. Male breast cancer (MBC) is an uncommon disease and there is limited information on the prognostic impact of routinely used clinicopathological parameters. Material and methods. In a retrospective setting, we reviewed 197 MBC patients with accessible paraffin-embedded tumor tissue and clinicopathological data. Immunohistochemical (IHC) stainings were performed on tissue microarrays and histological grading on conventional slides. Cox proportional regression models were applied for uni- and multivariate analyses using breast cancer death as the event. Results. Estrogen receptor (ER) and progesterone receptor positivity were demonstrated in 93% and 77% of patients, respectively. Nottingham histologic grade (NHG) III was seen in 41% and HER2 positivity in 11%. Classification into molecular subtypes using IHC markers according to three alternative definitions revealed luminal A and luminal B in 81% vs. 11%; 48% vs. 44% and 41% vs. 42% of cases. Two cases of basal-like were identified, but no cases of HER2-like. Factors associated with an increased risk of breast cancer death were node positivity (HR 4.5; 95% CI 1.8-11.1), tumor size andgt;20 mm (HR 3.3; 95% CI 1.4-7.9) and ER negativity (HR 10.9; 95% CI 3.2-37.9). No difference in breast cancer death between the luminal subgroups was demonstrated, regardless of definition. Conclusion. MBC tumors were more often of high grade, whereas HER2 overexpression was as frequent as in FBC. Lymph nodes, tumor size and ER status were independent predictors of breast cancer death. The prognostic impact of molecular subtyping in MBC seems to differ from that previously established in FBC.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a MEDICINE
653 a MEDICIN
7001 a Johansson, Idau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden4 aut0 (Swepub:lu)med-ijo
7001 a Ahlin, Ceciliau Department of Oncology, Örebro University Hospital, Örebro, Sweden4 aut
7001 a Thorstenson, Stenu Linköpings universitet,Onkologi,Hälsouniversitetet,Department of Pathology, Linköping University Hospital, Linköping, Sweden4 aut0 (Swepub:liu)steth53
7001 a Amini, Rose-Marieu Uppsala universitet,Molekylär och morfologisk patologi,Uppsala University, Sweden4 aut0 (Swepub:uu)roseamin
7001 a Holmqvist, Maritu Uppsala-Örebro Regional Oncologic Center, Uppsala, Sweden4 aut
7001 a Bergkvist, Leifu Uppsala universitet,Centrum för klinisk forskning, Västerås,Lund University, Sweden4 aut0 (Swepub:uu)leber451
7001 a Hedenfalk, Ingridu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden4 aut0 (Swepub:lu)onk-ifa
7001 a Fjällskog, Marie-Louiseu Uppsala universitet,Enheten för onkologi,Uppsala University, Sweden4 aut0 (Swepub:uu)marifjal
7102 a Uppsala universitetb Centrum för klinisk forskning, Västerås4 org
7730 t Acta Oncologicad : Informa Healthcareg 52:1, s. 102-109q 52:1<102-109x 0284-186Xx 1651-226X
8564 u http://dx.doi.org/10.3109/0284186X.2012.711952y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88364
8564 8u https://doi.org/10.3109/0284186X.2012.711952
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172675
8564 8u https://lup.lub.lu.se/record/3480971

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy